Axelopran

Drug Profile

Axelopran

Alternative Names: Oral Peripheral Mu Opioid Receptor Antagonist; TD-1211

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Aza compounds; Benzamides; Cyclohexanes; Heterocyclic bicyclo compounds; Laxatives; Small molecules; Tropanes
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Constipation

Most Recent Events

  • 14 Aug 2015 Phase-II development is ongoing for opioid-induced constipation in USA
  • 02 Jun 2014 Theravance Biopharma is formed as a spin-off of Theravance
  • 23 May 2014 Theravance completes a phase I trial in healthy volunteers in USA (NCT01702194)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top